Kyverna Therapeutics

Our team is always excited to showcase important research in autoimmune disease, especially in areas where transformative options are needed like #StiffPersonSyndrome (SPS). That’s why we want to congratulate the team at University of Colorado who is presenting a retrospective analysis at the American Academy of Neurology Annual Meeting #AANAM, highlighting the importance of specific clinical measures in SPS. The analysis focuses on timed 25-foot walk (T25FW), a clinical test used to measure walking speed and mobility in patients with SPS -- and the primary endpoint in our pivotal SPS clinical trial, KYSA-8. Learn more: https://lnkd.in/e23b5JCs

Today, we announced our Q4 and Full Year 2024 Financial Results and shared our latest business updates. We had a strong year as we solidified our leadership in autoimmune CAR T and advanced our lead asset in our three priority indications -- #StiffPersonSyndrome, #MyastheniaGravis and #LupusNephritis, each with a clear and rapid path to market. Read more about our latest progress and our financial results here: https://lnkd.in/e7daFW3w   #AutoimmuneDisease #CARTCellTherapy

Check out the new The Stiff Person Syndrome Research Foundation (The SPSRF) podcast episode, proudly sponsored by Kyverna. This conversation with Amanda Piquet, MD, FAAN and Tara Zier, Founder of The Stiff Person Syndrome Research Foundation, is packed with valuable insights and helpful resources for those impacted by #SPS. Don't miss out on learning about the latest advancements, including #CARTcelltherapy, and how we can support the SPS community together. To learn more, listen in to the full episode here: https://lnkd.in/g7cPnNnS #AutoimmuneDisease #StiffPersonSyndrome  

Kyverna is proud to sponsor the upcoming The Stiff Person Syndrome Research Foundation (The SPSRF) podcast featuring Amanda Piquet, MD, FAAN and Tara Zier, Founder of The Stiff Person Syndrome Research Foundation. In their conversation, they will debunk common misconceptions around #StiffPersonSyndrome, share insights on where the future of treatment is heading, and provide tools and strategies for patients coping with #SPS. Tune in to the full episode on March 25th at 7 PM EST: https://lnkd.in/eCh8ZEFV

Today, on #InternationalSPSAwarenessDay (Stiff Person Syndrome), it’s important that we come together and shine a light on this progressive and rare autoimmune disease that most commonly causes muscle stiffness and painful spasms. At Kyverna, we are dedicated to advancing our research in CAR T to offer transformative outcomes in SPS and other autoimmune diseases. Together, we can raise awareness, drive research forward, and bring hope to those in need.  #SPS #StiffPersonSyndrome #CARTCellTherapy #AutoimmuneDisease    Learn more: https://lnkd.in/eSZ882FR

Promoting positive change in Stiff Person Syndrome starts with raising awareness and advocating for improved care and support for those affected by #AutoimmuneDisease. Join us in spreading the word about ongoing research for #StiffPersonSyndrome, aiming to enhance options and quality of life. Learn more: www.SPStrials.com

We look forward to presenting at the Leerink Partners Global Biopharma Conference on March 10 and engaging with attendees who share our commitment to advancing cell therapy for autoimmune diseases. Learn more: https://lnkd.in/enDVvgCV #AutoimmuneDisease #Biopharma

On #RareDiseaseDay, we proudly stand with patients, caregivers, and the global community to raise awareness of how innovation can improve the lives of those impacted. We are dedicated to advancing CAR T-cell therapies for rare autoimmune diseases, driving progress toward transformative treatments. Together, let's unite to make a difference. #MyastheniaGravis #StiffPersonSyndrome

Our Head of Medical Affairs, Europe, Philipp Krüger, facilitated a Tech Talk at The EBMT-European Hematology Association (EHA) 7th European CAR T-cell Meeting last week, highlighting Kyverna’s investigational next-generation CAR T program, which is designed to improve patient access for those affected by autoimmune diseases.   #CART25 #autoimmunedisease #CARTCellTherapy #EHA #EBMT

We’re excited to announce that Naji GEHCHAN, MD, MBA, has joined us to serve as our Chief Medical and Development Officer. Dr. Gehchan brings a wealth of U.S. and international experience to Kyverna across multiple therapeutic areas, including immunology, successfully driving complex development programs to commercialization. His leadership and drive for operational excellence will be instrumental as we urgently progress the clinical development priorities that lie ahead for the company. #CARTCellTherapy #autoimmunedisease  To learn more: https://lnkd.in/gQJwyrEA